“PI3Kα is one of the most important, well-validated, and heavily pursued disease drivers in oncology, but its therapeutic potential has been constrained by wild-type PI3Kα-mediated toxicity and incomplete coverage of clinically relevant mutations,” said Rob Kania, Ph.D., Chief Executive Officer of KymaThera. “Our drug design objective from the outset was to address these limitations. K-1728 possesses class-leading potency with helical mutant selectivity windows wider than any reported to date. This financing, backed by an exceptional syndicate of leading life sciences investors, gives us the resources to rapidly advance K-1728 into the clinic and pursue its potential across cancer and vascular malformations.”